Department of Experimental Hematooncology, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Arch Immunol Ther Exp (Warsz). 2020 Nov 6;68(6):34. doi: 10.1007/s00005-020-00599-x.
Chimeric antigen receptor (CAR)-T cells (CART) remain one of the most advanced and promising forms of adoptive T-cell immunotherapy. CART represent autologous, genetically engineered T lymphocytes expressing CAR, i.e. fusion proteins that combine components and features of T cells as well as antibodies providing their more effective and direct anti-tumour effect. The technology of CART construction is highly advanced in vitro and every element of their structure influence their mechanism of action in vivo. Patients with haematological malignancies are faced with the possibility of disease relapse after the implementation of conventional chemo-immunotherapy. Since the most preferable result of therapy is a partial or complete remission, cancer treatment regimens are constantly being improved and customized to individual patients. This individualization could be ensured by CART therapy. This paper characterized CART strategy in details in terms of their structure, generations, mechanism of action and published the results of clinical trials in haematological malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and multiple myeloma.
嵌合抗原受体 (CAR)-T 细胞 (CART) 仍然是最先进和最有前途的过继性 T 细胞免疫疗法形式之一。CART 代表自体、基因工程化的表达 CAR 的 T 淋巴细胞，即融合蛋白，其结合了 T 细胞的组成部分和特征以及抗体，提供更有效和直接的抗肿瘤作用。CART 构建的技术在体外非常先进，其结构的每个元素都影响其体内的作用机制。接受常规化疗-免疫治疗后，血液系统恶性肿瘤患者面临疾病复发的可能。由于治疗的最理想结果是部分或完全缓解，癌症治疗方案不断得到改进和针对个体患者进行定制。CART 疗法可以确保这种个体化。本文详细描述了 CART 策略在结构、代际、作用机制方面的特点，并公布了包括急性淋巴细胞白血病、弥漫性大 B 细胞淋巴瘤、慢性淋巴细胞白血病和多发性骨髓瘤在内的血液系统恶性肿瘤的临床试验结果。
